Tanya Kothari

Congratulations to the management team on delivering another quarter of healthy business growth and continued improvement in asset quality. I just have a couple of questions. The Board has approved raising up to around ₹7,000 crores to equity or BASEL III instrument. What is the expected timeline and preferred route for the capital raising?

Sir, the liquidity coverage ratio declined from 235% to 156% and also NSFR reduced from 147% to 128%, but both remain above regulatory requirements, but the fall is very sharp. Can you elaborate on it, sir?

Sir, the advance grew was very strong 28.6% year-on-year ahead of the industry growth?